^
    Back
    Association details:
    Biomarker:CTNNB1 mutation
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Clin Cancer Res
    Title:

    Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

    Excerpt:
    ...2 of 10 with PIK3CA mutations, 1 of 9 with PTEN mutations, and 1 of 2 with CTNNB1 mutations responded to panitumumab.
    DOI:
    10.1158/1078-0432.CCR-12-1913